Here are 1-3 brief analogies for CeriBell:

• CeriBell is like the Dexcom for brain activity, providing continuous, real-time seizure monitoring for critically ill hospital patients.
• It's the 'Uber' for electroencephalography (EEG) in hospitals, making a critical brain activity diagnostic available quickly and easily at the patient's bedside with AI.
• Think of it as an AI-powered 'Apple Watch for the brain' for acute care patients, enabling rapid and continuous seizure detection.

• Disposable Headbands: Single-use hardware components for the Ceribell System, designed to rapidly capture patient EEG signals.
• Clarity AI-powered Seizure Detection Algorithm: A subscription-based artificial intelligence algorithm that continuously monitors EEG signals to aid clinicians in real-time seizure detection and diagnosis.
• EEG Recorders and Portal Access: A subscription service providing use of portable, battery-operated EEG recorders and access to an online portal for data management and system interface.

CeriBell (CBLL) sells its products and services primarily to other companies, specifically hospitals and acute care facilities. The company's customer base includes a range of institutions, from top academic centers to small community hospitals.

As of September 30, 2024, CeriBell had over 500 active accounts. However, the provided background information does not name specific customer companies or their public symbols, as these are typically healthcare providers and not publicly traded companies in the traditional sense.

Jane Chao, PhD - President, Chief Executive Officer, Co-Founder, and Director

Jane Chao is a co-founder of CeriBell and has served as its CEO since October 2015. Prior to joining CeriBell, Dr. Chao held positions as Principal Manager of Portfolio Management Strategy at Genentech, Inc. and Senior Strategy Manager at Novartis AG. She also worked as a management consultant at McKinsey & Company. She holds a Ph.D. in biophysics from Cornell University.

Scott Blumberg - Chief Financial Officer

Scott Blumberg has served as CeriBell's CFO since April 2020. He founded Venture Forward Advisory Services, a financial and strategic consulting agency, where he acted as an outsourced CFO and trusted advisor to over 20 venture-backed startups. Earlier in his career, he was Director of Business Development for IDEV Technologies, a venture-backed medical device company, and led the M&A process that resulted in its sale to Abbott for $310 million. Mr. Blumberg also worked as an investment professional at Bay City Capital, a life sciences venture capital firm, and an investment banking analyst at Bank of America.

Raymond Woo, PhD - Chief Technology Officer

Raymond Woo joined CeriBell in 2016 and leads its product research and development efforts. Before CeriBell, Dr. Woo was Global Head of Femtosecond Laser R&D at Abbott Medical Optics (now part of J&J Vision). He also contributed to the development of the Catalys laser cataract surgery system at Optimedica, which was subsequently acquired by Abbott Medical Optics. He holds a Ph.D. and Master's degree in Electrical Engineering from Stanford University.

Sean Manni - Chief Revenue Officer

Sean Manni brings over 25 years of experience in the healthcare industry to CeriBell.

Diku Mandavia, MD - Chief Medical Officer

Dr. Diku Mandavia is a recognized expert in emergency medicine with more than 25 years of clinical experience and nearly 15 years in the commercial medical device sector. He is focused on advancing CeriBell's mission to establish a new standard of care through non-invasive brain monitoring.

• Market Adoption and Resistance to Changing Established Clinical Practices: CeriBell aims to transform the diagnosis and management of neurological conditions and expand the use of EEG in acute care settings, a market they believe is significantly underutilized. Despite the demonstrated benefits of the Ceribell System, there is a substantial risk that healthcare facilities and clinicians may be slow to adopt new technologies and change established practices, which could hinder the company's ability to achieve its goal of becoming the standard of care and fully realize its estimated $2 billion market opportunity.
• Reliance on Regulatory Clearances and Favorable Reimbursement Policies: The company's current success and future growth are heavily dependent on obtaining and maintaining regulatory approvals, such as the FDA 510(k) clearance for seizure diagnosis and FDA Breakthrough Device Designation for delirium detection. Future expansion into new indications and international markets will require additional regulatory clearances, which can be time-consuming and uncertain. Furthermore, CeriBell's revenue generation relies on favorable reimbursement policies, including the New Technology Add-on Payment (NTAP) from CMS. Any adverse changes in regulatory requirements or reimbursement policies could significantly impact the company's ability to market its product and generate revenue.
• Dependence on Expansion and Effectiveness of Direct Sales Organization: CeriBell plans to expand the size of its direct sales organization in the United States to drive further adoption and utilization of the Ceribell System. There is a risk that the company may not be able to effectively scale its sales force, recruit and retain qualified personnel, or ensure the productivity of its sales team. Failure to successfully expand and manage its sales organization could impede market penetration, limit customer acquisition, and consequently hinder revenue growth.

CeriBell (CBLL) anticipates several key drivers for future revenue growth over the next 2-3 years:

• Growth in Active Accounts and Utilization: The company plans to expand its direct sales organization in the United States to drive further adoption of the Ceribell System by acquiring new customers and increasing the utilization of the system within existing active accounts. This strategy focuses on increasing both the number of hospitals using the system and the frequency of its use for patient monitoring.
• Expansion to New Indications: CeriBell intends to leverage its proprietary database of EEG recordings and AI capabilities to expand the use of its system beyond seizure detection. This includes pursuing additional indications, such as the detection and monitoring of delirium, for which it has already received an FDA Breakthrough Device Designation. This expansion into new applications for the Ceribell System is expected to open up significant new market opportunities.
• International Market Expansion: While currently focused on the United States, CeriBell has received a CE Mark for the Ceribell System in Europe and plans to pursue additional regulatory clearances there within two to four years. The company also intends to engage in market access initiatives in other attractive international regions, signaling a strategic move to broaden its geographic reach and revenue streams outside of the U.S.
• Increased Sales Force: CeriBell intends to expand the size of its direct sales organization in the United States, including Territory Managers for new customer acquisition and Clinical Account Managers for ongoing account coverage and increased utilization. This investment in its sales team is expected to directly support the growth in its active account base and overall system utilization.